| Name | Title | Contact Details |
|---|
MediMedia Information Technologies (MMIT) was founded to assist health plans in the printing and distribution of their formulary documents. Over the last 25 years, MMIT has expanded and strengthened its relationships throughout the industry, developed innovative technology, and capitalized on trends to become the leading provider of multichannel formulary information solutions.
CCA Industries, Inc. (CCA) is engaged in the health and beauty aids business, selling numerous products in several health and beauty aids and cosmeceutical categories.
Marathon Health is based in Indianapolis, IN and Winooski, VT. When we say we are a different kind of healthcare company, we mean we`re a better kind. What makes us better is that we guide people to take control of their own health. We operate on a simple premise: when people are given the tools they need to manage their own health and healthcare, the cost of healthcare is lower. We believe the best way to keep people healthy is to help them manage risk factors and chronic conditions, and to keep them from getting sick in the first place. To do this, we combine a powerful collection of onsite health services into a program tailored to your unique culture, setting, and workforce.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Kemberton is a leading provider of technology-enabled revenue cycle management services to hospitals for complex claims. We specialize in the management and collection of workers compensation, motor vehicle accident claims, veteran administration and the resolution of insurance denials for hospitals and physician practice groups. Kemberton helps accelerate collection times and maximize reimbursements for over 300 hospital clients across 35 states, resulting in over $1.5 billion dollars of incremental cash payments for our clients.